Clinical Trials Logo

Deafness clinical trials

View clinical trials related to Deafness.

Filter by:

NCT ID: NCT03861442 Completed - Hearing Loss Clinical Trials

Front-End Processing 3.0

FEP3
Start date: April 1, 2019
Phase:
Study type: Observational

This study investigated the impact of Automatic Sound Management 3.0 (i.e. ambient noise reduction, transient noise reduction and an adaptive intelligence) as implemented in the SONNET2 on CI users' speech performance and their subjective quality of hearing and device handling.

NCT ID: NCT03859648 Terminated - Clinical trials for Hearing Loss, Conductive

BONEBRIDGE Bone Conduction Implant in Adults

Start date: August 26, 2019
Phase: N/A
Study type: Interventional

Approximately thirty subjects with mixed or conductive hearing loss, meeting FDA-cleared candidacy criteria for the BONEBRIDGE, will be implanted and followed for three (3) months post-activation to assess safety and effectiveness of the BONEBRIDGE implant.

NCT ID: NCT03848910 Completed - Clinical trials for Conductive Hearing Loss

Subject´s Preference Regarding Hearing Performance and Functionality Using a New Sound Processor

Start date: February 19, 2019
Phase: N/A
Study type: Interventional

The aim of this clinical investigation is to investigate the subject´s overall preference, hearing performance and self-reported assessments with the Investigational device and its precursor Sound Processor (Comparator) after 6 weeks in subjects with conductive/mixed hearing loss or Single Sided Deafness, (SSD).

NCT ID: NCT03834714 Completed - Clinical trials for Hearing Loss, Noise-Induced

Noise Exposure and Near-Infrared Light

Start date: February 18, 2020
Phase: N/A
Study type: Interventional

The primary objective of this work is to determine the effect noise has on the auditory system (both auditory health and performance) and also the degree to which the effect of pre-noise therapy such as Near Infrared (NIR) light can mitigate the effects of noise exposure.

NCT ID: NCT03817242 Completed - Clinical trials for Hearing Loss,Conductive

Half-thickness Tragal Cartilage Graft vs Temporalis Fascia Graft Tympanoplasty Type I

PTA
Start date: January 1, 2017
Phase: N/A
Study type: Interventional

The rationale of this study is to find out the surgical outcome and success rates of tragal cartilage and temporalis fascia, subsequently to develop guide line in light of the results of this study for our department as our institute is going to follow one patient in one bed policy in future. The purpose of this study is to compare the graft success rate of cartilage versus temporalis fascia in tympanoplasty type I in our institute, as no such study has been conducted in our province before.

NCT ID: NCT03807713 Completed - Mixed Hearing Loss Clinical Trials

Clinical Study of Minimally Invasive Ponto Surgical Technique (MIPS) - Design Iteration

Start date: September 7, 2018
Phase: N/A
Study type: Interventional

The objective of the study is to compare the outcomes after a surgical procedure with minimally invasive Ponto surgery (MIPS, test group) and tissue preservation surgery (control) for placing Oticon Medical Ponto implants and abutments.

NCT ID: NCT03803943 Recruiting - Clinical trials for Hearing Loss, Bilateral

Early Communication Intervention for Toddlers With Hearing Loss

Start date: June 15, 2019
Phase: Phase 2
Study type: Interventional

Improving spoken language outcomes for children with hearing loss has important public health implications. This is a randomized clinical trial of 96 children with hearing loss that examines the effects of a parent-implemented early communication intervention on prelinguistic and spoken language outcomes. The study is open for national recruitment. Parents participate via video call with their child and receive technology to assist with virtual visits.

NCT ID: NCT03771287 Completed - Clinical trials for Hearing Loss, Sensorineural

Hearing Aid Noise Reduction in Pediatric Users (Oticon Study)

OtiS
Start date: December 5, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the efficacy of OpenSound Navigator (OSN), a hearing aid speech-enhancement algorithm developed by Oticon, as treatment for pediatric hearing aid users. Using a double-blind experimental design, the investigators aim to compare two treatment groups of pediatric (ages 6-12) patients with symmetrical sensorineural hearing losses ranging from the mild to moderately-severe degree. One group will be fit with bilateral Oticon OPN™ behind-the-ear hearing aids set with an omni-directional microphone setting. The other group will be fit with the same hearing aid model with the OSN algorithm enabled. Participants from the groups will be age and audiogram-matched. The investigators will evaluate hearing aid benefit through word recognition in noise (behavioral testing) and everyday hearing/listening abilities (parental/legal guardian reported) at hearing aid fitting and 6-8 months post fitting.

NCT ID: NCT03766152 Completed - Clinical trials for Hearing Loss, Conductive

Audiological Benefit and Improved Quality of Life With Two Bone Conduction Systems: ADHEAR vs. Bonebridge in Experienced Users

Start date: November 1, 2018
Phase: N/A
Study type: Interventional

Patients implanted with a Bonebridge will be asked to be part of the study. The study subjects are enrolled into the study according to inclusion criteria. Patients will be asked to wear an adhesive bone conduction device an adapt to it for 30-60 min. After this time period patients will be asked to use the adhesive device instead of the Bonebridge for 3 weeks. Audiologic Tests and quality of life questionnaires will be assessed at the beginning of the study and at the end of three weeks.

NCT ID: NCT03756337 Completed - Clinical trials for Hearing Loss, Sensorineural

Neuro 1 vs. Neuro 2 Sound Processors

Start date: November 1, 2019
Phase: N/A
Study type: Interventional

This study evaluates the benefit of Neuro 1 sound processor upgrade in speech perfomance in adults. Half of participants will be tested with Neuro 1 first and Neuro 2, while the other half will be tested with Neuro 2 first and then Neuro 1.